You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
PerkinElmer will provide biochemical and genetic testing to support BioMarin's testing program aimed at Batten disease and mucopolysaccharidosis disorders.
The company's Eonis assay, which leverages RT-PCR technology, can be used to simultaneously tests for SMA, SCID, and XLA in newborns.
A number of diagnostic labs have considered saliva-based SARS-CoV-2 testing but decided against it, while other groups continue to pursue it.
The firm's Diagnostics segment revenues shot up 46 percent while its Discovery & Analytical Solutions segment revenues retreated 10 percent.
The company is providing DNA/RNA extraction kits, viral RNA isolation platforms, workstations, and kits for detecting nucleic acids from the coronavirus to the lab.
The test is the second from Euroimmun to receive EUA from the agency. Its antibody test received the designation last Month.
Sema4 said it will provide SARS-CoV-2 viral and antibody testing to Connecticut residents including state employees and first responders.
Reuters reports federal investigators are looking into PerkinElmer's role in an alleged Medicare fraud, though the firm says it is unaware of any investigation.
The company's Diagnostics segment was down 2 percent year over year, while its Discovery & Analytical Solutions segment grew 2 percent.
Seegene said Monday that the Health Canada approval will enable hospitals and licensed labs there to run the assay immediately for high-volume testing.
The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.
A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.
NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.
In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.